Kidney transplant drug boosts immune activity in breast cancer

Share this article:

The immunosuppressant agent daclizumab, which is used to prevent acute organ rejection in persons undergoing renal transplants, has now been shown to improve survival by 30% in patients with breast cancer who received a therapeutic vaccine.

Robert H. Vonderheide, MD, DPhil, and James Riley, PhD, both of the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, led a team that theorized daclizumab could effectively deplete regulatory T cells (Tregs) and restore the immune system's ability to fight tumors. As the investigators wrote in Science Translational Medicine (2012;4[134]:134ra62), Tregs are key mediators of immune tolerance and feature prominently in cancer. Tumor cells draw Tregs to the tumor area, where the Tregs rely on the protein IL-2 for most of their functions.

Daclizumab is a monoclonal antibody that binds to the CD25 receptor on the surfaces of Tregs, depriving the cells of IL-2. The lack of IL-2 forces Tregs to convert into normal T cells that no longer surround the tumor, allowing immune cells to make their way in to battle the tumor.

To learn more about the impact of daclizumab on Tregs in humans, Vonderheide, Riley, and colleagues performed a clinical trial of daclizumab in combination with an experimental cancer vaccine being developed at their facility. Among the 10 study participants, all of whom had metastatic breast cancer, the agent worked “incredibly well,” said Vonderheide in an announcement from the medical school: The T-cell conversion lasted 2 months and no side effects were detected. Although the tumors did not shrink, they did stop growing in six of the patients. The patients receiving the vaccine plus daclizumab survived about 7 months longer than those given vaccine only.

Because Tregs can block the immune response against most human cancers, “Drugs like daclizumab might be useful for most cancer patients, especially those receiving other types of immune therapy,” noted Vonderheide.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Breast cancer is more accurately diagnosed after PET/CT imaging in younger patients

A change in diagnosis resulted from PET/CT imaging of patients who were younger than 40 years with an initial diagnosis of stage I-III breast cancer, according to a retrospective analysis.

Gigapixel camera provides resolution and whole-body imaging for taking a "skin cancer ...

A gigapixel camera that takes high-resolution snapshots of the entire body could prove to be a new tool for whole-body skin cancer screening.

Targeting a unique receptor promising for glioblastoma multiforme

Glioblastoma multiforme (GBM) is one of the most lethal primary brain tumors, but new therapeutic strategies are being investigated.